

CSL ORDER APAS® INDEPENDENCE FOR GLOBAL QC OPERATIONS

APAS® instrument supplied under 5-year lease with 6-month minimum period for evaluation of global rollout potential

Adelaide, Australia, 09 June 2026: Leaders in AI microbiology automation, Clever Culture Systems Ltd (ASX: CC5) (**CCS** or the **Company**), is pleased to announce an order from CSL Behring (**CSL**) for the lease of an APAS® Independence instrument and environmental monitoring analysis modules. The instrument will be delivered to CSL under an all-inclusive 5-year lease contract with monthly instalments throughout the term.

Highlights:

- **APAS® instrument to be leased to CSL with monthly lease payments inclusive of service, analysis module and installation fees**
- **An evaluation will assess the potential for APAS® Independence to deliver benefits across the CSL global manufacturing network**
- **CSL order reflects execution of CCS's sales strategy focused on large global pharmaceutical manufacturers**
- **Global large pharmaceutical companies with APAS® Independence increases to 8**

Brent Barnes, CCS CEO and Managing Director said:

"We are delighted to welcome CSL to our growing list of global pharmaceutical partners. CSL's manufacturing network spans Australia, Europe and the US, and this evaluation is a direct expression of our strategy to place APAS® Independence at the heart of quality control operations in the world's leading biopharmaceutical facilities. A successful outcome here opens the door to a significant multi-site deployment opportunity, and we look forward to demonstrating the performance of APAS® Independence and building a foundation for exactly that."

Craig Stephens, CSL Global Head of QC Technical Services said:

"At CSL, maintaining the highest standards of quality across our manufacturing operations is fundamental. Part of this commitment involves regularly assessing technologies that may enhance our operational workflows, further supporting the patients we deliver. This evaluation will allow us to assess the performance of APAS® Independence and its integration within our existing laboratory systems. The outcomes will help inform whether this technology could support broader standardisation of microbiology quality control practices across CSL's global manufacturing network."

APAS® Independence order from CSL

CCS have received an order from CSL to lease an APAS® Independence. The instrument is leased to CSL under a bundled contract, inclusive of service, analysis module software and installation fees. The contract will be paid in monthly instalments, with an initial minimum non-cancellable period of 6 months following commencement of the CSL formal validation (no later than 31 December 2026). The total value of the lease payments is based upon instrument and analysis module pricing previously disclosed to the market, with an appropriate uplift allowing for the lease style contract. Legal ownership passes to CSL at the end of the lease term (5-years).

CSL will initially undertake an evaluation and validation to assess the performance of APAS® Independence compared to manual plate reading, as well as integration within CSL's existing environmental monitoring processes and laboratory information management system. Lease payments will commence when CSL formally start their evaluation, expected within 6 months following installation. The evaluation will take place at the Broadmeadows facility in Melbourne and assess the potential for APAS® Independence to be deployed throughout the CSL manufacturing network.

CSL order expands number of global pharmaceutical manufacturers using APAS® Independence

The delivery to CSL will further expand the number of global pharmaceutical manufacturers actively using or evaluating the APAS® Independence. These customers typically commence with an initial evaluation of the technology to demonstrate the performance of the system, before deploying the instrument to other sites.

Approved for release by the CCS Board.



– ENDS –

About Clever Culture Systems

Clever Culture Systems (CCS) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading. The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

Clever Culture Systems
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@cleverculturesystems.com